Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance

References

• Vasan N, Baselga J, Hyman DM, et al. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583–592.
   PubMed Web of Science ®Google Scholar
• Eruslanov EB, Singhal S, Albelda SM, et al. Mouse versus human neutrophils in cancer: a major knowledge gap. Trends Cancer. 2017;3(2):149–160.
   PubMed Web of Science ®Google Scholar
• Xie X, Shi Q, Wu P, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol. 2020;21(9):1119–1133.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20:485–503.
   PubMed Web of Science ®Google Scholar
• Ng LG, Ostuni R, Hidalgo A, et al. Heterogeneity of neutrophils. Nat Rev Immunol. 2019;19(4):255–265.
   PubMed Web of Science ®Google Scholar
• Tak T, Tesselaar K, Pillay J, et al. What’s your age again? determination of human neutrophil half-lives revisited. J Leukoc Biol. 2013;94(4):595–601.
   PubMed Web of Science ®Google Scholar
• Lakschevitz FS, Visser MB, Sun C, et al. Neutrophil transcriptional profile changes during transit from bone marrow to sites of inflammation. Cell Mol Immunol. 2015;12(1):53–65.
   PubMed Web of Science ®Google Scholar
• Ethier J-L, Desautels D, Templeton A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res BCR. 2017;19(1):2.
   PubMed Web of Science ®Google Scholar
• Kang J, Chang Y, Ahn J, et al. Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: a cohort study. Int J Cancer. 2019;145(12):3267–3275.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Strauss L, Sangaletti S, Consonni FM, et al. RORC1 regulates tumor-promoting “Emergency” granulo-monocytopoiesis. Cancer Cell. 2015;28(2):253–269.
   PubMed Web of Science ®Google Scholar
• Zilionis R, Engblom C, Pfirschke C, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):e10.
   Web of Science ®Google Scholar
• Evrard M, Kwok IWH, Chong SZ, et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity. 2018;48(2):e8.
   Web of Science ®Google Scholar
• Zhou G, Peng K, Song Y, et al. CD177+ neutrophils suppress epithelial cell tumourigenesis in colitis-associated cancer and predict good prognosis in colorectal cancer. Carcinogenesis. 2018;39(2):272–282.
   PubMed Web of Science ®Google Scholar
• Engblom C, Pfirschke C, Zilionis R, et al. Osteoblasts remotely supply lung tumors with cancer-promoting siglecFhigh neutrophils. Science. 2017;358(6367).
   Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Gungabeesoon J, et al. Tumor-promoting Ly-6G+ SiglecFhigh Cells are mature and long-lived neutrophils. Cell Rep. 2020;32(12):108164.
   PubMed Web of Science ®Google Scholar
• Casbon A-J, Reynaud D, Park C, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A. 2015;112(6):E566–575.
   PubMed Web of Science ®Google Scholar
• Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562–573.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D, et al. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–348.
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Ni C, et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40(5):785–800.
   PubMed Web of Science ®Google Scholar
• Baumann T, Dunkel A, Schmid C, et al. Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal. Nat Immunol. 2020;21:555–566.
   PubMed Web of Science ®Google Scholar
• Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol Baltim Md 1950. 2009;183:937–944.
   Google Scholar
• Marini O, Costa S, Bevilacqua D, et al. Mature CD10+ and immature CD10- neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood. 2017;129(10):1343–1356.
   PubMed Web of Science ®Google Scholar
• Singhal S, Bhojnagarwala PS, O’Brien S, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30(1):120–135.
   PubMed Web of Science ®Google Scholar
• Germann M, Zangger N, Sauvain M-O, et al. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF β. EMBO Mol Med. 2020;12(1):e10681.
   PubMed Web of Science ®Google Scholar
• Governa V, Trella E, Mele V, et al. The interplay between neutrophils and CD8+ T Cells improves survival in human colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(14):3847–3858.
   PubMed Web of Science ®Google Scholar
• Wikberg ML, Ling A, Li X, et al. Neutrophil infiltration is a favorable prognostic factor in early stages of colon cancer. Hum Pathol. 2017;68:193–202.
   PubMed Web of Science ®Google Scholar
• Khanh DT, Mekata E, Mukaisho K, et al. Prognostic role of CD10+ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011;102(9):1724–1733.
   PubMed Web of Science ®Google Scholar
• Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through mac-1. J Clin Invest. 2012;122(1):327–336.
   PubMed Web of Science ®Google Scholar
• Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466–5480.
   PubMed Web of Science ®Google Scholar
• Andzinski L, Kasnitz N, Stahnke S, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138(8):1982–1993.
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Safi S, Blattner C, et al. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med. 2018;198(6):777–787.
   PubMed Web of Science ®Google Scholar
• Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16:601–620.
   PubMed Web of Science ®Google Scholar
• Carus A, Ladekarl M, Hager H, et al. Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. Br J Cancer. 2013;108(10):2116–2122.
   PubMed Web of Science ®Google Scholar
• Steele CW, Karim SA, Leach JDG, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832–845.
   PubMed Web of Science ®Google Scholar
• Kuang D-M, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54(5):948–955.
   PubMed Web of Science ®Google Scholar
• Wang J, Jia Y, Wang N, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12(1):7.
   PubMedGoogle Scholar
• He G, Zhang H, Zhou J, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res CR. 2015;34(1):141.
   PubMedGoogle Scholar
• Ilie M, Hofman V, Ortholan C, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012;118(6):1726–1737.
   PubMed Web of Science ®Google Scholar
• Zhou S-L, Zhou Z-J, Hu Z-Q, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150(7):e17.
   Web of Science ®Google Scholar
• Shojaei F, Singh M, Thompson JD, et al. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A. 2008;105(7):2640–2645.
   PubMed Web of Science ®Google Scholar
• Nozawa H, Chiu C, Hanahan D, et al. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493–12498.
   PubMed Web of Science ®Google Scholar
• Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol Baltim Md 1950. 2004;172:5034–5040.
   Google Scholar
• Mishalian I, Bayuh R, Eruslanov E, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-A new mechanism of impaired antitumor immunity. Int J Cancer. 2014;135(5):1178–1186.
   PubMed Web of Science ®Google Scholar
• Butin-Israeli V, Bui TM, Wiesolek HL, et al. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019;129(2):712–726.
   PubMed Web of Science ®Google Scholar
• Bui TM, Butin-Israeli V, Wiesolek HL, et al. Neutrophils alter DNA repair landscape to impact survival and shape distinct therapeutic phenotypes of colorectal cancer. Gastroenterology. 2021;(1). DOI:10.1053/j.gastro.2021.03.027.
   Web of Science ®Google Scholar
• Bui TM, Sumagin R. Progressing from recurring tissue injury to genomic instability: a new mechanism of neutrophil pathogenesis. DNA Cell Biol. 2019;38(8):747–753.
   PubMed Web of Science ®Google Scholar
• Glicksman R, Chaudary N, Pintilie M, et al. The predictive value of nadir neutrophil count during treatment of cervical cancer: interactions with tumor hypoxia and interstitial fluid pressure (IFP). Clin Transl Radiat Oncol. 2017;6:15–20.
   PubMed Web of Science ®Google Scholar
• Nguyen GT, Green ER, Mecsas J, et al. Neutrophils to the ROScue: mechanisms of NADPH Oxidase activation and bacterial resistance. Front Cell Infect Microbiol. 2017;7:373.
   PubMed Web of Science ®Google Scholar
• Cadet J, Davies KJA, Medeiros MH, et al. Formation and repair of oxidatively generated damage in cellular DNA. Free Radic Biol Med. 2017;107:13–34.
   PubMed Web of Science ®Google Scholar
• Mehta A, Haber JE. Sources of DNA double-strand breaks and models of recombinational DNA repair. Cold Spring Harb Perspect Biol. 2014;6(9):a016428.
   PubMed Web of Science ®Google Scholar
• Butin-Israeli V, Adam SA, Jain N, et al. Role of lamin B1 in chromatin instability. Mol Cell Biol. 2015;35(5):884–898.
   PubMed Web of Science ®Google Scholar
• Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23(7):247–251.
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, Rondinelli B, D’Andrea AD, et al. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52–64.
   PubMed Web of Science ®Google Scholar
• Negrini S, Gorgoulis VG, Halazonetis TD, et al. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–228.
   PubMed Web of Science ®Google Scholar
• Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 2011;3(1):66–74.
   PubMed Web of Science ®Google Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37(1):63–74.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2(2):83–90.
   PubMed Web of Science ®Google Scholar
• Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001;61:6400–6405.
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039–3051.
   PubMed Web of Science ®Google Scholar
• Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3779–3787.
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929–2934.
   PubMed Web of Science ®Google Scholar
• Massena S, Christoffersson G, Vågesjö E, et al. Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood. 2015;126(17):2016–2026.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450(7171):825–831.
   PubMed Web of Science ®Google Scholar
• Heldin C-H, Rubin K, Pietras K, et al. High interstitial fluid pressure — an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–813.
   PubMed Web of Science ®Google Scholar
• Itatani Y, Yamamoto T, Zhong C, et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci. 2020;117(35):21598–21608.
   PubMed Web of Science ®Google Scholar
• Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114–1123.
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57–64.
   PubMed Web of Science ®Google Scholar
• Li T-J, Jiang Y-M, Hu Y-F, et al. Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(6):1575–1585.
   PubMed Web of Science ®Google Scholar
• Pan B, Shen J, Cao J, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015;5(1):16053.
   PubMedGoogle Scholar
• Liu L, Sun H, Wu S, et al. IL‑17A promotes CXCR2‑dependent angiogenesis in a mouse model of liver cancer. Mol Med Rep. 2019;20:1065–1074.
   PubMed Web of Science ®Google Scholar
• Dökümcü K, Farahani RM Evolution of resistance in cancer: a cell cycle perspective. Front Oncol [Internet]. 2019. [ cited 2021 Apr 18]; 9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520611/.
   Google Scholar
• Greaves M, Maley CC. CLONAL EVOLUTION IN CANCER. Nature. 2012;481(7381):306–313.
   PubMed Web of Science ®Google Scholar
• Perego M, Tyurin VA, Tyurina YY, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med. 2020;12(572).
   Web of Science ®Google Scholar
• Albrengues J, Shields MA, Ng D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409).
   Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219–223.
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, Melaccio A, et al. Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. Clin Exp Med. 2015;15(2):145–150.
   PubMed Web of Science ®Google Scholar
• Mollaoglu G, Jones A, Wait SJ, et al. The lineage defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment. Immunity. 2018;49(4):e9.
   PubMed Web of Science ®Google Scholar
• Treffers LW, Ten Broeke T, Rösner T, et al. IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47-SIRPα checkpoint inhibition. Cancer Immunol Res. 2020;8(1):120–130.
   PubMed Web of Science ®Google Scholar
• Denis Musquer M, Jouand N, Pere M, et al. High-density of FcγRIIIA+ (CD16+) tumor-associated neutrophils in metastases improves the therapeutic response of cetuximab in metastatic colorectal cancer patients, independently of the HLA-E/CD94-NKG2A axis. Front Oncol. 2021;11:684478.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/ PD-1-mediated tumor immune escape. Mol Cancer [Internet]. 2019. [ cited 2021 Apr 18]; 18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332843/.
   Google Scholar
• Zamora AE, Crawford JC, Thomas PG, et al. Hitting the target: how T cells detect and eliminate tumors. J Immunol Baltim Md 1950. 2018;200:392–399.
   Google Scholar
• Lok LSC, Dennison TW, Mahbubani KM, et al. Phenotypically distinct neutrophils patrol uninfected human and mouse lymph nodes. Proc Natl Acad Sci U S A. 2019;116(38):19083–19089.
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.
   PubMed Web of Science ®Google Scholar
• Wang -T-T, Zhao Y-L, Peng L-S, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900–1911.
   PubMed Web of Science ®Google Scholar
• Xu W, Dong J, Zheng Y, et al. Immune-checkpoint Protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunol Res. 2019;7(9):1497–1510.
   PubMed Web of Science ®Google Scholar
• Sun L, Clavijo PE, Robbins Y, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019;4(7).
   Web of Science ®Google Scholar
• Strauss L, Mahmoud MAA, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43):eaay1863.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chandra V, Riquelme Sanchez E, et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217(12).
   Web of Science ®Google Scholar
• Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688–692.
   PubMed Web of Science ®Google Scholar
• Kargl J, Zhu X, Zhang H, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019;4(24).
   Web of Science ®Google Scholar
• Wagner NB, Weide B, Gries M, et al. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer. 2019;7(1):343.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Perez RP, Yardley D, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Res. 2020;22(1):4.
   PubMed Web of Science ®Google Scholar
• Nawa M, Osada S, Morimitsu K, et al. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. Anticancer Res. 2012;32:13–19.
   PubMed Web of Science ®Google Scholar